OBSERVANCE OF ANTIFIBROTIC TREATMENT IN THE FRENCH OPALE SUPPORT PROGRAM FOR PATIENTS WITH PULMONARY FIBROSIS
Author(s)
Stéphane Jouneau, MD1, Grégoire Prévot, MD2, Arnaud Constantin, MD3, Christian Agard, MD, PhD4, Sophie Gauthier, PhD5, Clara Bouvard, MSc6, Hugo Martin, PhD6, Marie Guillotin, MSc5, Corine Ghorayeb, MSc5, Coralie Hakibilen, PhD5, Bernard Aguilaniu, MD, PhD7.
1Respiratory Disease Department, Reference Center for Rare Pulmonary Diseases, Pontchaillou Hospital, IRSET UMR 1085, EHESP, Rennes University, Rennes, France, 2Department of Respiratory Medicine, Larrey University Hospital, Toulouse, France, 3Department of Rheumatology, Pierre-Paul Riquet University Hospital; INFINITY, INSERM UMR 1291, Purpan University Hospital, Toulouse University, Toulouse, France, 4Internal Medicine Department, Nantes University Hospital, Nantes, France, 5Patientys by Concentrix, Boulogne-Billancourt, France, 6RCTs, Lyon, France, 7HYLAB, Grenoble, France.
1Respiratory Disease Department, Reference Center for Rare Pulmonary Diseases, Pontchaillou Hospital, IRSET UMR 1085, EHESP, Rennes University, Rennes, France, 2Department of Respiratory Medicine, Larrey University Hospital, Toulouse, France, 3Department of Rheumatology, Pierre-Paul Riquet University Hospital; INFINITY, INSERM UMR 1291, Purpan University Hospital, Toulouse University, Toulouse, France, 4Internal Medicine Department, Nantes University Hospital, Nantes, France, 5Patientys by Concentrix, Boulogne-Billancourt, France, 6RCTs, Lyon, France, 7HYLAB, Grenoble, France.
OBJECTIVES: The OPALE program has been designed to bolster observance of antifibrotic treatments in patients with diffuse interstitial lung disease (ILD). The effectiveness of these treatments depends largely on therapeutic adherence, which is often vitiated by side effects. The objective of this study was to describe the evolution and maintenance of treatment observance among participants in the OPALE program.
METHODS: A retrospective analysis was carried out regarding patients in the OPALE program over the course of nine months. Observance was measured using the Girerd self administered questionnaire, and side effects were collected based on the participants’ declarations.
RESULTS: Among the 976 participants in the program, 319 definitively withdrew, including 187 due to treatment discontinuation; satisfactory treatment observance was noted in 67.4%. Notwithstanding distinct side effects, no difference regarding observance was noted among patients on nintedanib as opposed to pirfenidone; indeed, No single factor was associated with degree of treatment observance.
CONCLUSIONS: The OPALE program assessed observance of antifibrotic treatments among patients with ILD. Additional studies ensuring prospective assessment with more adapted tools are called for, the objectives being to confirm these results and to identify factors potentially impacting observance.
METHODS: A retrospective analysis was carried out regarding patients in the OPALE program over the course of nine months. Observance was measured using the Girerd self administered questionnaire, and side effects were collected based on the participants’ declarations.
RESULTS: Among the 976 participants in the program, 319 definitively withdrew, including 187 due to treatment discontinuation; satisfactory treatment observance was noted in 67.4%. Notwithstanding distinct side effects, no difference regarding observance was noted among patients on nintedanib as opposed to pirfenidone; indeed, No single factor was associated with degree of treatment observance.
CONCLUSIONS: The OPALE program assessed observance of antifibrotic treatments among patients with ILD. Additional studies ensuring prospective assessment with more adapted tools are called for, the objectives being to confirm these results and to identify factors potentially impacting observance.
Conference/Value in Health Info
2026-11, ISPOR Europe 2026, Vienna, Austria
Value in Health, Volume 29, Issue 12S
Code
PCR253
Topic
Patient-Centered Research
Topic Subcategory
Adherence, Persistence, & Compliance
Disease
Respiratory-Related Disorders (Allergy, Asthma, Smoking, Other Respiratory)